The week in industry: Collaboration launched to develop inhibitor for novel oncology target
This week: Avacta Group (Cambridge, UK) selects their clinical candidate from their Affimer Platform, the FDA grants accelerated approval of Genentech’s (CA, USA) treatment for patients with B-cell lymphoma and partnership announced to give UK SMEs access to novel mass spectrometry technologies.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>